Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL
Status:
Recruiting
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/CD22
bispecific chimeric antigen receptors (CARs) T cell therapy for CD19-positive Acute
Lymphoblastic Leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Collaborators:
First Affiliated Hospital of Wenzhou Medical University Hrain Biotechnology Co., Ltd. Second Affiliated Hospital of Nanchang University